Page 0035

RESEARCH AND DEVELOPMENT

35 CANCER CONTROL 2021

would not be expected to occur if survival from that cancer in

that country were as high as in another country, typically in the

same world region.

The overall aim of VENUSCANCER is to provide actionable

evidence for health policies to reduce the burden of women's

cancers worldwide.

Protocol

The protocol for data collection has been developed in

collaboration with over 300 cancer registries worldwide. This

has been a major undertaking in its own right.

Three VENUSCANCER Working Group meetings to discuss

the protocol were held during major international conferences

in Arequipa, Peru (12 November 2018) at the International

Association of Cancer Registries (IACR) conference; in

Vancouver, Canada (12 June 2019), during the North American

Association of Central Cancer Registries (NAACCR), and in

Moscow, Russian Federation, during the Second International

Forum of Oncology and Radiology (23 September 2019). The

discussion focused on the first aim of the project, to collect

detailed demographic, biological and clinical data for women

diagnosed with breast, ovarian or cervical cancer during the most recent year for which data are available, and in as many

countries as possible.

The ERC Consolidator grant enabled support to be provided

for visa, travel, accommodation and conference fees for

six colleagues from LMICs (Brazil, Cuba, Nigeria, Russian

Federation, South Africa, and Thailand), who would not

otherwise have been able to participate in these meetings.

Three questionnaires were developed to help refine the

protocol for data collection. The questionnaires were designed:

J To identify cancer registries that are willing to contribute

to this challenging part of the VENUSCANCER project.

J To identify which registries have data at the required level

of completeness.

J To identify which registries are willing to increase the

completeness of their data.

J To select cancer registries in LMICs that would be eligible

for financial support for data collection.

The questionnaires were presented during the

VENUSCANCER Working Group meetings. My research team

helped our colleagues to complete the questionnaires, and we

discussed which variables were more likely to be collected and

BREAST CERVIX OVARY

0102030405060708090100

§ Morocco

§ Nigeria

§ Algeria

§ South Africa

§† Mali

Mauritius *

Martinique *

Costa Rica *

Argentina

Puerto Rico *

Peru

Ecuador

§ Chile

§ Brazil

Cuba *

§ Colombia

§ Guadeloupe *

United States

Canada

§ Cyprus *

Japan

Israel *

Korea *

§ Jordan *

Taiwan *

Hong Kong *

China

Turkey

Singapore *

Mongolia *

Kuwait *

§ Qatar *

§ Thailand

India

§ Malaysia

Iceland *

Sweden *

Finland *

Norway *

Portugal *

Malta *

France

Netherlands *

Belgium *

Switzerland

Denmark *

Germany

Italy

United Kingdom *

Spain

Austria *

Slovenia *

§ Latvia *

Ireland *

Czech Republic *

Croatia *

Bulgaria *

Estonia *

Poland *

Slovakia *

Romania

Lithuania *

Russian Federation

Gibraltar *

Australia *

New Zealand *

0102030405060708090 100

§ Algeria

§ Nigeria

§ South Africa

Mauritius *

§ Costa Rica *

Cuba *

Puerto Rico *

Brazil

Martinique *

Peru

§ Chile

Uruguay *

Argentina

Ecuador

§ Colombia

§ Guadeloupe *

Canada

United States

Korea *

§ Cyprus *

Japan

Taiwan *

China

Israel *

Hong Kong *

§† Qatar *

Singapore *

Turkey

India

§ Malaysia

Kuwait *

§ Jordan *

§ Thailand

† Iceland *

Norway *

Switzerland

Denmark *

Sweden *

Netherlands *

Finland *

Italy

Estonia *

Portugal *

Slovenia *

Belgium *

Romania

Germany

France

Spain

Austria *

United Kingdom *

Ireland *

Croatia *

Czech Republic *

Slovakia *

Lithuania *

Russian Federation

Malta *

§ Latvia *

Poland *

Bulgaria *

New Zealand *

Australia *

0102030405060708090100

§† South Africa

§ Algeria

§ Nigeria

Mauritius *

Costa Rica *

§ Cuba *

Argentina

Ecuador

§ Uruguay *

Puerto Rico *

§ Martinique *

Brazil

§ Colombia

§† Guadeloupe *

§ Chile

United States

Canada

Taiwan *

Korea *

§ Malaysia

§ Cyprus *

Japan

Israel *

Singapore *

China

Turkey

§ Qatar *

Thailand

Kuwait *

India

Sweden *

Norway *

§ Latvia *

Switzerland

Portugal *

France

Belgium *

Estonia *

Germany

Finland *

Austria *

Iceland *

Spain

Denmark *

Italy

Poland *

Netherlands *

Bulgaria *

§ Romania

Slovenia *

Czech Republic *

United Kingdom *

Croatia *

Lithuania *

Russian Federation

Slovakia *

Ireland *

Malta *

Australia *

New Zealand *

Data completeness

0

20

Less than 25% 25-49% 50-74% 75-100%

20 20

20

10

4

17

5

13 13

4

8 8

Figure 1: Global distribution by continent and country of age-standardised 5-year net survival for women (15-99 years) diagnosed during 2010-14 with breast,

cervical or ovarian cancer

*Data with 100% coverage of the national population.

†National estimate not age-standardised.

§National estimate flagged as less reliable because the only available estimates are from a registry or registries in this category.

Index

  1. Page 0001
  2. Page 0002
  3. Page 0003
  4. Page 0004
  5. Page 0005
  6. Page 0006
  7. Page 0007
  8. Page 0008
  9. Page 0009
  10. Page 0010
  11. Page 0011
  12. Page 0012
  13. Page 0013
  14. Page 0014
  15. Page 0015
  16. Page 0016
  17. Page 0017
  18. Page 0018
  19. Page 0019
  20. Page 0020
  21. Page 0021
  22. Page 0022
  23. Page 0023
  24. Page 0024
  25. Page 0025
  26. Page 0026
  27. Page 0027
  28. Page 0028
  29. Page 0029
  30. Page 0030
  31. Page 0031
  32. Page 0032
  33. Page 0033
  34. Page 0034
  35. Page 0035
  36. Page 0036
  37. Page 0037
  38. Page 0038
  39. Page 0039
  40. Page 0040
  41. Page 0041
  42. Page 0042
  43. Page 0043
  44. Page 0044
  45. Page 0045
  46. Page 0046
  47. Page 0047
  48. Page 0048
  49. Page 0049
  50. Page 0050
  51. Page 0051
  52. Page 0052
  53. Page 0053
  54. Page 0054
  55. Page 0055
  56. Page 0056
  57. Page 0057
  58. Page 0058
  59. Page 0059
  60. Page 0060
  61. Page 0061
  62. Page 0062
  63. Page 0063
  64. Page 0064
  65. Page 0065
  66. Page 0066